Key Points
- Eric Venker, CEO of Roivant Sciences (NASDAQ: ROIV), sold 200,000 shares on December 9 at an average price of $20.85 for proceeds of $4.17 million, leaving him with 1,497,908 shares after the transaction.
- This December sale is one of many recent insider dispositions by Venker since late September — collectively amounting to roughly $45 million in sales — indicating a sustained pattern of large insider selling.
- Market and analyst context: ROIV opened at $21.34 (up 5.4%), trades near its 52‑week high, and carries a consensus rating of "Moderate Buy" with an average price target of $22.56.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00. Following the completion of the sale, the chief executive officer directly owned 1,497,908 shares in the company, valued at $31,231,381.80. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Eric Venker also recently made the following trade(s):
- On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.22, for a total transaction of $4,044,000.00.
- On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total transaction of $2,020,211.08.
- On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total value of $7,020,583.19.
- On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total value of $5,426,708.10.
- On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total value of $336,813.75.
- On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The stock was sold at an average price of $16.30, for a total value of $1,710,522.00.
- On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total value of $2,245,352.40.
- On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total transaction of $2,800,610.64.
- On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total transaction of $5,735,850.15.
- On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The shares were sold at an average price of $14.83, for a total transaction of $9,061,130.00.
Roivant Sciences Stock Up 5.4%
ROIV opened at $21.34 on Friday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $22.05. The company has a 50 day moving average of $19.26 and a two-hundred day moving average of $14.60. The company has a market cap of $14.84 billion, a P/E ratio of -38.11 and a beta of 1.22.
Institutional Investors Weigh In On Roivant Sciences
Hedge funds have recently bought and sold shares of the business. Bessemer Group Inc. raised its position in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Allworth Financial LP increased its stake in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after buying an additional 583 shares during the last quarter. Utah Retirement Systems increased its stake in shares of Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company's stock worth $312,000 after buying an additional 600 shares during the last quarter. Xponance Inc. raised its holdings in Roivant Sciences by 1.9% in the third quarter. Xponance Inc. now owns 46,718 shares of the company's stock valued at $707,000 after acquiring an additional 882 shares in the last quarter. Finally, CWM LLC boosted its stake in Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after acquiring an additional 920 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price target on Roivant Sciences from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Thursday, September 18th. Leerink Partners reiterated an "outperform" rating and set a $29.00 target price on shares of Roivant Sciences in a report on Tuesday, November 11th. HC Wainwright boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, September 18th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a "neutral" rating in a research report on Thursday, September 18th. Finally, Jefferies Financial Group lifted their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $22.56.
View Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
